Compare Recursion Pharmaceuticals Inc (RXRX) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Solaredge Technologies Inc trades at $35.12 (market cap $2.17B). The key difference: Solaredge Technologies Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | SEDG | |
|---|---|---|
Market Cap | $1.74B | $2.17B |
Sector | Health | Technology |
52-Week High | $6.79 | $78.51 |
52-Week Low | $2.84 | $28.47 |
Enterprise Value | $1.26B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
SolarEdge (SEDG) trades at $36.43, up 6.52% today, with a bullish technical signal despite negative profitability. Revenue declined to $1.18B in 2025, with a net loss of $405M, though recent quarterly EPS beat expectations. The stock shows improved cash flow from operations at $104M in 2025, and news highlights collaboration with Infineon for AI data center technology, driving positive sentiment.
Outlook remains cautious due to persistent losses and high debt, but analyst consensus price target of $41 offers 12.5% upside. Key risks include reliance on policy incentives and competitive pressures. Institutional sentiment is mixed with 23% buy ratings, suggesting patience for margin recovery and AI-related growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
